Clearing the Fog: Is Hydroxychloroquine Effective in Reducing Coronavirus Disease-2019 Progression? A Randomized...

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Conflicting data exists regarding the efficacy of hydroxychloroquine (HCQ) for treating COVID-19.
• Mild COVID-19 patients' disease progression and viral clearance require further investigation regarding HCQ treatment.

Purpose of the Study:

• To analyze the efficacy of hydroxychloroquine (HCQ) plus standard of care (SOC) versus SOC alone in reducing disease progression in mild COVID-19.
• To evaluate the impact of HCQ on viral clearance, measured by PCR negativity at days 7 and 14.

Main Methods:

• A single-center, open-label randomized controlled trial was conducted with 500 mild COVID-19 patients.
• Patients were assigned to either HCQ plus SOC (n=349) or SOC alone (n=151).
• Primary outcome was disease progression; secondary outcomes included PCR negativity on days 7 and 14.

Main Results:

• No significant difference in disease progression was observed between the HCQ group (3.15%) and the control group (3.3%) (p=0.940).
• PCR negativity on day 7 was significantly higher in the HCQ group (52.1%) compared to the control group (35.8%) (p=0.001).
• No significant differences were found in PCR negativity on day 14 (p=0.508) or consecutive PCR negativity on days 7 and 14 (p=0.321).

Conclusions:

• Adding hydroxychloroquine to standard care for mild COVID-19 does not prevent disease progression.
• Hydroxychloroquine does not significantly aid in early or sustained viral clearance in mild COVID-19 patients.
• The study suggests limited benefit of HCQ in the management of mild COVID-19 cases.